RLAY (Relay Therapeutics) Total Liabilities: $77.45 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLAY Relay Therapeutics Inc RLAY
46 GF Score
Price $20.08
GF Value $3.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Relay Therapeutics Total Liabilities?

Relay Therapeutics RLAY +0.40% 46 Total Liabilities is $77.45 Mil as of Jun. 2026. GuruFocus rates RLAY with a GF Score™ of 46/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Relay Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was $77.45 Mil.

Relay Therapeutics's quarterly Total Liabilities increased from Dec. 2025 ($54.27 Mil) to Mar. 2026 ($57.43 Mil) and increased from Mar. 2026 ($57.43 Mil) to Jun. 2026 ($77.45 Mil).

Relay Therapeutics's annual Total Liabilities increased from Dec. 2023 ($91.98 Mil) to Dec. 2024 ($93.50 Mil) but then declined from Dec. 2024 ($93.50 Mil) to Dec. 2025 ($54.27 Mil).

Relay Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Relay Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relay Therapeutics Total Liabilities Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 110.64 149.55 91.98 93.50 54.27

Relay Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.18 62.29 54.27 57.43 77.45
RLAY
46GF Score
Relay Therapeutics Inc RLAY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relay Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Relay Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=25.578+(28.693+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.27

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=621.331-567.06
=54.27

Relay Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=50.804+(26.644+-7.105427357601E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=77.45

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=967.457-890.009
=77.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $77.45 Mil mean?
Relay Therapeutics (RLAY) has a Total Liabilities of $77.45 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Relay Therapeutics and its competitors.
Is Relay Therapeutics' Total Liabilities too high?
Relay Therapeutics' current Total Liabilities is $77.45 Mil. Overall, Relay Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Total Liabilities compare to CELC and VKTX?
Relay Therapeutics' Total Liabilities of $77.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Relay Therapeutics and its competitors. Relay Therapeutics's current Total Liabilities is $77.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.08 — trading 428.4% above its estimated fair value. The current Total Liabilities is $77.45 Mil. Relay Therapeutics' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Total Liabilities is $77.45 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relay Therapeutics (RLAY) Overvalued in 2026?

Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued. The current stock price of $20.08 is trading 428.4% above its estimated GF Value™ of $3.80. GuruFocus considers Relay Therapeutics to be Significantly Overvalued.

Key valuation signals for RLAY:

  • Total Liabilities: $77.45 Mil
  • GF Value™: $3.80 vs. price of $20.08 (428.4% above fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relay Therapeutics Business Description

Address 60 Hampshire Street, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
46GF Score

Get the complete analysis for RLAY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.08
Price
$3.80
GF Value